Bristol-Myers Squibb Company (BMY)
Automate Your Wheel Strategy on BMY
With Tiblio's Option Bot, you can configure your own wheel strategy including BMY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BMY
- Rev/Share 23.4418
- Book/Share 8.5941
- PB 5.264
- Debt/Equity 2.9211
- CurrentRatio 1.2068
- ROIC 0.1328
- MktCap 91798156294.0
- FreeCF/Share 7.1636
- PFCF 6.297
- PE 18.1776
- Debt/Assets 0.5379
- DivYield 0.0545
- ROE 0.2957
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | BMY | Daiwa Securities | Outperform | Neutral | -- | $42 | Aug. 5, 2025 |
| Initiation | BMY | Cantor Fitzgerald | -- | Neutral | -- | $55 | April 22, 2025 |
| Initiation | BMY | Piper Sandler | -- | Overweight | -- | -- | April 22, 2025 |
| Upgrade | BMY | Jefferies | Hold | Buy | -- | $70 | Dec. 16, 2024 |
| Resumed | BMY | BofA Securities | -- | Neutral | -- | $63 | Dec. 10, 2024 |
| Initiation | BMY | Bernstein | -- | Market Perform | -- | $56 | Oct. 17, 2024 |
News
Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key Facts
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Neutral
Bristol Myers Squibb (BMY) closed the most recent trading day at $59.21, moving +0.03% from the previous trading session.
Read More
2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT
Published: March 14, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of 2seventy bio, Inc. (NasdaqGS: TSVT) to Bristol Myers Squibb (NYSE: BMY). Under the terms of the proposed transaction, shareholders of 2seventy will receive $5.00 in cash for each share of 2seventy that they own. KSF is seeking to determine whether this consideration and the process that led to.
Read More
Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal
Published: March 11, 2025 by: Benzinga
Sentiment: Positive
On Monday, Bristol Myers Squibb & Co BMY agreed to acquire 2seventy bio, Inc. TSVT at $5.00 per share in an all-cash transaction for a total equity value of approximately $286 million, or $102 million net of estimated cash.
Read More
EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCC
Published: March 10, 2025 by: Zacks Investment Research
Sentiment: Neutral
The EC approves BMY's combination of Opdivo and Yervoy for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma.
Read More
Bristol-Myers Squibb Company (BMY) Presents at 45th Annual TD Cowen Health Care Conference (Transcript)
Published: March 04, 2025 by: Seeking Alpha
Sentiment: Neutral
Bristol-Myers Squibb Company (NYSE:BMY ) 45th Annual TD Cowen Health Care Conference March 4, 2025 2:30 PM ET Company Participants Adam Lenkowsky - Executive Vice President & Chief Commercial Officer Conference Call Participants Steve Scala - Cowen Steve Scala Well, good afternoon once again. Welcome to TD Cowen's 45th Annual Healthcare Conference.
Read More
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
Published: February 26, 2025 by: The Motley Fool
Sentiment: Positive
Healthcare is considered a defensive industry, since good medical care is needed regardless of economic or market conditions. Therefore many companies in this sector are somewhat insulated from the impact of economic downturns.
Read More
Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success
Published: February 21, 2025 by: Seeking Alpha
Sentiment: Positive
Bristol-Myers Squibb has shown exceptional success in addressing challenges directly related to the introduction of generic versions of Revlimid and Sprycel. So, the gem in its oncology franchise is Breyanzi, whose sales amounted to $263 million in the fourth quarter of 2024, an increase of 160.4% year-on-year. On the other hand, Camzyos is gradually becoming the flagship of Bristol-Myers Squibb's cardiovascular franchise.
Read More
BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing
Published: February 20, 2025 by: PRNewsWire
Sentiment: Neutral
STOCKHOLM , Feb. 20, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic and its partner Bristol Myers Squibb (NYSE: BMY) have received clearance from the U.S. Federal Trade Commission (FTC) for BioArctic to out-license its PyroGlutamate-amyloid-beta (PyroGlu-Aβ) antibody program to Bristol Myers Squibb. Closing of the agreement has been completed and BioArctic will receive an upfront payment of USD 100 million.
Read More
Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer
Published: February 19, 2025 by: Business Wire
Sentiment: Neutral
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--BMS Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant.
Read More
BMY Down 7% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Negative
Bristol Myers' lackluster guidance for 2025 warrants caution. We recommend investors to wait and watch for the time being as generic competition for legacy drugs is a major headwind.
Read More
Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma
Published: February 10, 2025 by: Business Wire
Sentiment: Neutral
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb Announces Positive Topline Results for Breyanzi in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma.
Read More
About Bristol-Myers Squibb Company (BMY)
- IPO Date 1972-06-01
- Website https://www.bms.com
- Industry Drug Manufacturers - General
- CEO Christopher S. Boerner
- Employees 34100